Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gemolac
- Development stage
- Unknown
- Lead developer
- Allgems Healthcare
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Gemolac is an oral probiotic supplement developed by Allgems Healthcare, categorized within their gastrointestinal (GI) branded generics portfolio. It is indicated for the maintenance of gastrointestinal health and the treatment of dysbiosis, a condition involving an imbalance of the gut's microbial community. As a probiotic, Gemolac introduces beneficial live microorganisms into the digestive tract to restore the natural flora, which may be disrupted by factors such as antibiotic therapy, infections, or poor diet. Its mechanism of action involves the competitive exclusion of pathogenic bacteria, the production of antimicrobial substances (such as organic acids), and the enhancement of the intestinal mucosal barrier and local immune response. It is typically used to manage digestive upsets, including diarrhea and irritable bowel syndrome (IBS).
- Brand names
- Gemolac
Beyond the preview
Go deeper on Gemolac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gemolac.